RxDoctor Payments Data

Gwen Dalphon, PA

Medical · Newark, DENPI 1245574250

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (59.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Incyte Corporation at 57.0% of the total. 2025 is the largest year on record at $51,793, more than ten times the $1,612 reported in 2021. Among medical clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$116,437in general payments, 2019–2025

Across 895 payments — averaging $130.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$66K
  • Galderma Laboratories, L.p.$27K
  • Johnson & Johnson$4K
  • Eli Lilly$4K
  • Regeneron Healthcare Solutions, Inc.$3K
  • Lilly USA, LLC$2K
  • plus $10K from 25 others

What the payments were for

  • Consulting fees$16,21114%
  • Speaking & faculty fees$69,01059%
  • Travel & lodging$10,2119%
  • Food & beverage$20,28617%
  • Education$7191%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$116,437 in reported general payments places this provider in the 95th percentile of 73 medical providers in Delaware.

See all medical providers in Delaware

Medicare billing

Part B allowed, 2024
$349,542
Medicare patients
841
Services billed
4,658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Metronidazole66$3,049
Clobetasol Propionate49$2,787
Doxycycline Hyclate28$1,483
Ketoconazole79$1,307
Azelaic Acid11$1,126
Triamcinolone Acetonide73$693
Nystatin37$463
ValacyclovirValacyclovir Hcl21$418
Mupirocin36$221
Hydrocortisone18$107
Prednisone11$47

Paid to pharmacies, not to this prescriber.

Other medical in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →